Keertan Dheda1,2, Laura Lenders1, Gesham Magombedze3, Shashikant Srivastava3, Prithvi Raj4, Erland Arning5, Paula Ashcraft5, Teodoro Bottiglieri5, Helen Wainwright6, Timothy Pennel7, Anthony Linegar7, Loven Moodley7, Anil Pooran1, Jotam G Pasipanodya3, Frederick A Sirgel8, Paul D van Helden8, Edward Wakeland4, Robin M Warren8, Tawanda Gumbo1,3. 1. 1 Center for Lung Infection and Immunity, Division of Pulmonology and University of Cape Town Lung Institute, Department of Medicine. 2. 2 Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. 3. 3 Center for Infectious Diseases Research and Experimental Therapeutics and. 4. 4 Department of Immunology, University of Texas Southwestern Medical Center, Dallas, Texas. 5. 5 Institute of Metabolic Disease, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas. 6. 6 Department of Pathology and. 7. 7 Chris Barnard Division of Cardiothoracic Surgery, Department of Surgery, Groote Schuur Hospital and University of Cape Town, Cape Town, South Africa. 8. 8 Division of Molecular Biology and Human Genetics, South African Medical Research Council Centre for Tuberculosis Research/Department of Science and Technology/National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, Stellenbosch University, Stellenbosch, South Africa.
Abstract
RATIONALE: Acquired resistance is an important driver of multidrug-resistant tuberculosis (TB), even with good treatment adherence. However, exactly what initiates the resistance and how it arises remain poorly understood. OBJECTIVES: To identify the relationship between drug concentrations and drug susceptibility readouts (minimum inhibitory concentrations [MICs]) in the TB cavity. METHODS: We recruited patients with medically incurable TB who were undergoing therapeutic lung resection while on treatment with a cocktail of second-line anti-TB drugs. On the day of surgery, antibiotic concentrations were measured in the blood and at seven prespecified biopsy sites within each cavity. Mycobacterium tuberculosis was grown from each biopsy site, MICs of each drug identified, and whole-genome sequencing performed. Spearman correlation coefficients between drug concentration and MIC were calculated. MEASUREMENTS AND MAIN RESULTS: Fourteen patients treated for a median of 13 months (range, 5-31 mo) were recruited. MICs and drug resistance-associated single-nucleotide variants differed between the different geospatial locations within each cavity, and with pretreatment and serial sputum isolates, consistent with ongoing acquisition of resistance. However, pretreatment sputum MIC had an accuracy of only 49.48% in predicting cavitary MICs. There were large concentration-distance gradients for each antibiotic. The location-specific concentrations inversely correlated with MICs (P < 0.05) and therefore acquired resistance. Moreover, pharmacokinetic/pharmacodynamic exposures known to amplify drug-resistant subpopulations were encountered in all positions. CONCLUSIONS: These data inform interventional strategies relevant to drug delivery, dosing, and diagnostics to prevent the development of acquired resistance. The role of high intracavitary penetration as a biomarker of antibiotic efficacy, when assessing new regimens, requires clarification.
RATIONALE: Acquired resistance is an important driver of multidrug-resistant tuberculosis (TB), even with good treatment adherence. However, exactly what initiates the resistance and how it arises remain poorly understood. OBJECTIVES: To identify the relationship between drug concentrations and drug susceptibility readouts (minimum inhibitory concentrations [MICs]) in the TB cavity. METHODS: We recruited patients with medically incurable TB who were undergoing therapeutic lung resection while on treatment with a cocktail of second-line anti-TB drugs. On the day of surgery, antibiotic concentrations were measured in the blood and at seven prespecified biopsy sites within each cavity. Mycobacterium tuberculosis was grown from each biopsy site, MICs of each drug identified, and whole-genome sequencing performed. Spearman correlation coefficients between drug concentration and MIC were calculated. MEASUREMENTS AND MAIN RESULTS: Fourteen patients treated for a median of 13 months (range, 5-31 mo) were recruited. MICs and drug resistance-associated single-nucleotide variants differed between the different geospatial locations within each cavity, and with pretreatment and serial sputum isolates, consistent with ongoing acquisition of resistance. However, pretreatment sputum MIC had an accuracy of only 49.48% in predicting cavitary MICs. There were large concentration-distance gradients for each antibiotic. The location-specific concentrations inversely correlated with MICs (P < 0.05) and therefore acquired resistance. Moreover, pharmacokinetic/pharmacodynamic exposures known to amplify drug-resistant subpopulations were encountered in all positions. CONCLUSIONS: These data inform interventional strategies relevant to drug delivery, dosing, and diagnostics to prevent the development of acquired resistance. The role of high intracavitary penetration as a biomarker of antibiotic efficacy, when assessing new regimens, requires clarification.
Entities:
Keywords:
acquired drug resistance; drug gradient; lung cavity; sputum MIC; whole-genome sequencing
Authors: Keertan Dheda; Jason D Limberis; Elize Pietersen; Jody Phelan; Aliasgar Esmail; Maia Lesosky; Kevin P Fennelly; Julian Te Riele; Barbara Mastrapa; Elizabeth M Streicher; Tania Dolby; Abdallah M Abdallah; Fathia Ben-Rached; John Simpson; Liezel Smith; Tawanda Gumbo; Paul van Helden; Frederick A Sirgel; Ruth McNerney; Grant Theron; Arnab Pain; Taane G Clark; Robin M Warren Journal: Lancet Respir Med Date: 2017-01-19 Impact factor: 30.700
Authors: Jotam G Pasipanodya; Helen McIlleron; André Burger; Peter A Wash; Peter Smith; Tawanda Gumbo Journal: J Infect Dis Date: 2013-07-29 Impact factor: 5.226
Authors: Keertan Dheda; Tawanda Gumbo; Neel R Gandhi; Megan Murray; Grant Theron; Zarir Udwadia; G B Migliori; Robin Warren Journal: Lancet Respir Med Date: 2014-03-24 Impact factor: 30.700
Authors: Elize Pietersen; Elisa Ignatius; Elizabeth M Streicher; Barbara Mastrapa; Xavier Padanilam; Anil Pooran; Motasim Badri; Maia Lesosky; Paul van Helden; Frederick A Sirgel; Robin Warren; Keertan Dheda Journal: Lancet Date: 2014-01-17 Impact factor: 79.321
Authors: Tawanda Gumbo; Arnold Louie; Mark R Deziel; Linda M Parsons; Max Salfinger; George L Drusano Journal: J Infect Dis Date: 2004-09-24 Impact factor: 5.226
Authors: Tawanda Gumbo; Arnold Louie; Mark R Deziel; Weiguo Liu; Linda M Parsons; Max Salfinger; George L Drusano Journal: Antimicrob Agents Chemother Date: 2007-08-27 Impact factor: 5.191
Authors: Grant Theron; Jason Limberis; Rouxjeane Venter; Liezel Smith; Elize Pietersen; Aliasgar Esmail; Greg Calligaro; Julian Te Riele; Marianna de Kock; Paul van Helden; Tawanda Gumbo; Taane G Clark; Kevin Fennelly; Robin Warren; Keertan Dheda Journal: Nat Med Date: 2020-06-29 Impact factor: 53.440
Authors: Devyani Deshpande; Jan-Willem C Alffenaar; Claudio U Köser; Keertan Dheda; Moti L Chapagain; Noviana Simbar; Thomas Schön; Marieke G G Sturkenboom; Helen McIlleron; Pooi S Lee; Thearith Koeuth; Stellah G Mpagama; Sayera Banu; Suporn Foongladda; Oleg Ogarkov; Suporn Pholwat; Eric R Houpt; Scott K Heysell; Tawanda Gumbo Journal: Clin Infect Dis Date: 2018-11-28 Impact factor: 9.079
Authors: Alvaro A Ordonez; Hechuan Wang; Gesham Magombedze; Camilo A Ruiz-Bedoya; Shashikant Srivastava; Allen Chen; Elizabeth W Tucker; Michael E Urbanowski; Lisa Pieterse; E Fabian Cardozo; Martin A Lodge; Maunank R Shah; Daniel P Holt; William B Mathews; Robert F Dannals; Jogarao V S Gobburu; Charles A Peloquin; Steven P Rowe; Tawanda Gumbo; Vijay D Ivaturi; Sanjay K Jain Journal: Nat Med Date: 2020-02-17 Impact factor: 53.440
Authors: Michael E Urbanowski; Alvaro A Ordonez; Camilo A Ruiz-Bedoya; Sanjay K Jain; William R Bishai Journal: Lancet Infect Dis Date: 2020-05-05 Impact factor: 25.071